In a report issued on March 9, Silvio Micheloto from Mizuho Securities maintained a Buy rating on Marathon Petroleum (MPC – Research Report), with a price target of $70.00. The company’s shares closed last Monday at $77.17, close to its 52-week high of $81.39.
According to TipRanks.com, Micheloto is a 5-star analyst with an average return of 52.5% and a 96.7% success rate. Micheloto covers the Utilities sector, focusing on stocks such as Delek US Holdings, Valero Energy, and Hollyfrontier.
Marathon Petroleum has an analyst consensus of Strong Buy, with a price target consensus of $84.33, representing an 8.5% upside. In a report issued on March 8, Scotiabank also maintained a Buy rating on the stock with a $85.00 price target.
Based on Marathon Petroleum’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $35.34 billion and net profit of $774 million. In comparison, last year the company earned revenue of $17.97 billion and had a net profit of $285 million.
Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MPC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1887, Ohio-based Marathon Petroleum Corp. is a petroleum refining company, which is engaged in refining, marketing, retailing, and transporting petroleum products primarily in the United States. It operates through three segments: Refining & Marketing, Retail, and Midstream.
Read More on MPC:
- Mizuho Securities Reaffirms Their Hold Rating on Toast Inc (TOST)
- BHP Group Ltd (BHPLF) Gets a Hold Rating from Jefferies
- Talkspace (TALK) Gets a Hold Rating from Robert W. Baird
- Mizuho Securities Maintains a Buy Rating on Automatic Data Processing (ADP)
- Leerink Partners Keeps a Hold Rating on Ionis Pharmaceuticals (IONS)